Aspen Neuroscience Raises $147.5M in Series B Financing

DamienMcDevitt PhD, president and chief executive officer of Aspen Neuroscience, Inc.

Aspen Neuroscience, Inc., San DiegoPrivate biotechnology company based in CA that develops autologous cell therapies. This includes the first iPSC-derived neuron replacement treatment. Parkinson’s disease (PD), closed its $147.5m Series BRound of funding 

GV, LYFE CapitalAnd Revelation PartnersParticipated in the round as a co-leader, with additional investors participating. Newton Investment Management, SingaporeEDBI, a global investor based in the United States LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset CapitalNS InvestmentOther. TheIncluded investments in raising Series A/SeedInvestment teams that include ARCH, OrbiMed and ARCH Venture Partners, Frazier Life SciencesSection 32 and Alexandria Venture Investments. AsPart of the financing Doug Fisher of Revelation Partners will join the boardThis is directors.

The company intends to use the funds to conduct the planned studies of its lead product candidate for Parkinson’s disease, ANPD001, including its patient Screening CohortThe future and study Phase 1/2a clinical trial, post-IND submission to FDA.

Aspen NeurosciencePrivate biotechnology company in development that focuses on personalized (autologous cell therapy). TheCompany is developing induced-pluripotent (iPSCs), which are used to treat diseases with high unmet medical needs. They begin with autologous neuron replacements for both sporadic as genetic forms. Parkinson’s disease (PD) and extending across the brain and affected organs. An iPSC platform company, Aspen combines stem cell biology with the latest artificial intelligence and genomic approaches to investigate patient-specific, restorative treatments. TheCompany has created a platform that allows for the creation and characterisation of pluripotent-derived cells medicines. in-Inhouse bioinformatics and manufacturing.



Leave a Comment